World's Best Scientists 2026 revealed!
Animesh Pardanani

Animesh Pardanani

D-Index & Metrics

Medicine

D-Index
111
Citations
47996
World Ranking
5316
National Ranking
2869

Overview

Animesh Pardanani is affiliated with the Mayo Clinic in the United States and has contributed extensively to the field of medical research, with a particular focus on hematology. Their body of work encompasses a wide range of topics primarily related to hematological disorders and malignancies.

Their research is prominently featured in several high-impact publication venues. Frequent journals where their work appears include:

  • Blood
  • American Journal of Hematology
  • Blood Cancer Journal
  • Haematologica
  • British Journal of Haematology

Their main field of study is Medicine, with a strong emphasis on several subfields:

  • Hematology
  • Genetics
  • Molecular Biology
  • Rheumatology
  • Immunology

Animesh Pardanani's research addresses numerous key topics, including:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Eosinophilic Disorders and Syndromes
  • Kruppel-like factors research
  • Hemoglobinopathies and Related Disorders
  • Mast cells and histamine

The scientist has collaborated frequently with several researchers, including:

  • Ayalew Tefferi
  • Naseema Gangat
  • Mrinal M. Patnaik
  • Aref Al-Kali
  • Kebede H. Begna

Some notable recent publications authored or co-authored by Animesh Pardanani include:

  • Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management, 2023, American Journal of Hematology
  • Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management, 2021, American Journal of Hematology
  • Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera, 2020, British Journal of Haematology
  • Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients, 2020, American Journal of Hematology (co-authored)
  • Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network (co-authored)

This profile underscores Animesh Pardanani's involvement in advancing understanding and clinical approaches within blood cancers and related hematological conditions through prolific research contributions combined with extensive collaboration in the field.

Best Publications

  • Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

    Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani

  • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman

  • DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

    Naseema Gangat;Domenica Caramazza;Rakhee Vaidya;Geeta George

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Mutations and prognosis in primary myelofibrosis

    Alessandro Maria Vannucchi;Tl Lasho;Paola Guglielmelli;Flavia Biamonte

  • Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study

    A Tefferi;E Rumi;G Finazzi;H Gisslinger

  • Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis

    Ayalew Tefferi;Paola Guglielmelli;Dirk R. Larson;Christy Finke

  • Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

    Ross L. Levine;Animesh Pardanani;Ayalew Tefferi;D. Gary Gilliland

  • Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

    Ken Hong Lim;Ayalew Tefferi;Terra L. Lasho;Christy Finke

  • CALR vs JAK2 vs MPL -mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

    A Tefferi;T L Lasho;C M Finke;R A Knudson

  • Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

    Ayalew Tefferi;Rakhee Vaidya;Rakhee Vaidya;Domenica Caramazza;Domenica Caramazza;Christy Finke;Christy Finke

  • TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

    A. Tefferi;A. Pardanani;K. H. Lim;K. H. Lim;O. Abdel-Wahab

  • MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

    Paola Guglielmelli;Terra L. Lasho;Giada Rotunno;Mythri Mudireddy

  • Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

    Animesh Pardanani;Jason R. Gotlib;Catriona Jamieson;Jorge E. Cortes

  • Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

    Animesh Pardanani;Claire Harrison;Jorge E. Cortes;Francisco Cervantes

  • CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

    Animesh Pardanani;Animesh Pardanani;Animesh Pardanani;Rhett P. Ketterling;Rhett P. Ketterling;Rhett P. Ketterling;Stephanie R. Brockman;Stephanie R. Brockman;Stephanie R. Brockman;Heather C. Flynn;Heather C. Flynn;Heather C. Flynn

  • Treatment of hypereosinophilic syndrome with imatinib mesilate

    Gerald J Gleich;Kristin M Leiferman;Animesh Pardanani;Ayalew Tefferi

  • Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    Ayalew Tefferi;Francisco Cervantes;Ruben Mesa;Francesco Passamonti

  • FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

    Animesh Pardanani;Stephanie R. Brockman;Sarah F. Paternoster;Heather C. Flynn

  • A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

    Ruben A. Mesa;David P. Steensma;David P. Steensma;Animesh Pardanani;Animesh Pardanani;Chin Yang Li;Chin Yang Li

Frequent Co-Authors

Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Terra L. Lasho
Terra L. Lasho Mayo Clinic
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Paola Guglielmelli
Paola Guglielmelli University of Florence

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA is a significant commitment, but there are several related online degrees and pathways that can enable a healthcare career or specialization. Many students consider direct-entry options when transitioning into nursing or advancing their practice. For those interested in a streamlined path, direct entry nursing programs can be an efficient choice, especially for those with a non-nursing background.

If you want to become a registered nurse, another accessible pathway is the direct entry msn programs online, offering a faster route to advanced nursing roles even for non-nurses. For practicing nurses aiming to elevate their credentials, understanding the average cost of rn to bsn programs is essential, as affordability can vary widely.

For advanced research or academic positions, online doctoral options are increasingly popular. Many choose phd in nursing online programs that offer flexibility for working professionals. Exploring these various online pathways can help students find the best route for their goals while managing costs and timelines.

Best Scientists Citing Animesh Pardanani

Trending Scientists